MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Minimal residual disease (MRD) ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief driver of relapse for patients. For years, detecting MRD has relied on invasive ...